The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Open accessAbstract
Funder: \n Bundesministerium für Bildung und Forschung\n https://doi.org/10.13039/501100002347
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Self-citationWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02232-10 · Cited by 1,108
Self-citationMatsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., & Taguchi, F. (2010) · Journal of Virology · doi:10.1128/jvi.01542-10 · Cited by 778
Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S., & Gallagher, T. (2011) · Journal of Virology · doi:10.1128/jvi.02062-10 · Cited by 693
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Shirato, K., Kawase, M., & Matsuyama, S. (2013) · Journal of Virology · doi:10.1128/jvi.01890-13 · Cited by 453
Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J. M., Nelson, P. S., Pöhlmann, S., & Soilleux, E. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035876 · Cited by 398
Self-citationGierer, S., Bertram, S., Kaup, F., Wrensch, F., Heurich, A., Krämer-Kühl, A., Welsch, K., Winkler, M., Meyer, B., Drosten, C., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00128-13 · Cited by 341
Self-citationYamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J.-I., & Matsuda, Z. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01043-16 · Cited by 340
Cited by
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,197
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
Self-citationDrug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
COVID-19-associated coagulopathy and disseminated intravascular coagulation
Asakura, H., & Ogawa, H. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03029-y · Cited by 442
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 339
Metadata
- Authors
- Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C., & Pöhlmann, S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-05-21
- Volume
- 64
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W3017258575
- Cited by
- 486
- References
- 13
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. https://app.cochat.ai/papers/10.1128/aac.00754-20
- The paper
- Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00754-20
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.